Cibinqo (abrocitinib) Letter of Medical Necessity
Cibinqo (abrocitinib) is an oral JAK1 inhibitor for refractory atopic dermatitis. Its FDA label restricts use to patients who have failed other systemic therapy including biologics, so payers almost universally require a documented Dupixent or other systemic trial. Strong documentation of that failure and of boxed-warning risk assessment is the core of an approvable request.
FDA-Approved Indications
- ● refractory moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older not adequately controlled with other systemic drugs, including biologics, or when those therapies are inadvisable
Why Cibinqo Prior Authorization Gets Denied
The most common denial reasons across major payers:
- 1. Prior systemic therapy, including a biologic such as Dupixent, not documented (label requirement)
- 2. EASI, IGA, or BSA not documented at baseline
- 3. Boxed-warning risk factors (age, smoking, cardiovascular, thrombosis, malignancy history) not addressed
- 4. Baseline CBC, lipid panel, TB, and hepatitis screening not on file
- 5. Concurrent biologic or other immunosuppressant use
What to Include in a Cibinqo Letter of Medical Necessity
Document baseline EASI, IGA, BSA, and itch scores, topical therapy failures, prior systemic and biologic therapies with dose, duration, and reason for discontinuation, an individualized risk assessment for the JAK inhibitor boxed warnings, and baseline CBC, lipids, TB, and hepatitis screening.
Key clinical evidence to cite:
- ✓ JADE MONO-1 and JADE MONO-2 — significant IGA and EASI-75 response vs placebo
- ✓ JADE COMPARE — rapid itch relief vs dupilumab and placebo with background topical therapy
- ✓ JADE DARE — head-to-head vs dupilumab with faster itch response and higher EASI-90 at week 16
- ✓ JADE TEEN — efficacy in adolescents 12 to 17 years
Relevant guidelines:
- 📖 AAD Atopic Dermatitis Guidelines (2023 update)
- 📖 JTF Atopic Dermatitis Practice Parameter (2023)
Cibinqo Prior Authorization Criteria
Standard criteria across major US payers for Cibinqo. Specific criteria vary by plan — RxCheckUp tailors each LMN to your patient's exact payer policy.
Typical step therapy requirements:
- → Prior systemic therapy, including a biologic such as Dupixent, not documented (label requirement)
Required documentation:
- ✓ ICD-10 diagnosis code with specificity
- ✓ Prior therapy history with dates, doses, and discontinuation reasons
- ✓ Specialist evaluation (where applicable)
- ✓ Baseline disease activity or biomarker results
- ✓ Clinical rationale citing FDA labeling or guidelines
Approval details:
Initial approval: typically 6 months. Renewal: 12 months with documented clinical response.
Payers Covering Cibinqo
RxCheckUp tailors each LMN to the specific payer's medical policy and step therapy requirements:
Cibinqo Prior Authorization FAQ
Why was my Cibinqo prior authorization denied?
The most common denial reasons for Cibinqo are: Prior systemic therapy, including a biologic such as Dupixent, not documented (label requirement); EASI, IGA, or BSA not documented at baseline; Boxed-warning risk factors (age, smoking, cardiovascular, thrombosis, malignancy history) not addressed; Baseline CBC, lipid panel, TB, and hepatitis screening not on file; Concurrent biologic or other immunosuppressant use.
What should a Cibinqo Letter of Medical Necessity include?
Document baseline EASI, IGA, BSA, and itch scores, topical therapy failures, prior systemic and biologic therapies with dose, duration, and reason for discontinuation, an individualized risk assessment for the JAK inhibitor boxed warnings, and baseline CBC, lipids, TB, and hepatitis screening.
Which payers cover Cibinqo?
Cibinqo is covered by major US payers including UnitedHealthcare, Aetna, Cigna, Anthem BCBS, Humana, Medicare Part D, though formulary tier and prior authorization criteria vary.